Article Sidebar

pdf
Date Published: 15/04/2024
Abstract Views: 95
Views pdf: 97
DOI: https://doi.org/10.51298/vmj.v537i2.9250
Issue
Vol. 537 No. 2 (2024)
Section
Các bài báo
How to Cite
Phan, A. S. Q., & Phạm, T. B. Đào. (2024). OVERVIEW OF ADVERSE EFFECTS IN PATIENTS UNDERGOING CHEMOTHERAPY WITH THE R-CHOP REGIMEN FOR NON-HODGKIN’S LYMPHOMA IN THE HEAD AND NECK REGION. Vietnam Medical Journal, 537(2). https://doi.org/10.51298/vmj.v537i2.9250

OVERVIEW OF ADVERSE EFFECTS IN PATIENTS UNDERGOING CHEMOTHERAPY WITH THE R-CHOP REGIMEN FOR NON-HODGKIN'S LYMPHOMA IN THE HEAD AND NECK REGION

Anh Sỹ Quế Phan, Thị Bích Đào Phạm

Main Article Content

Abstract

Objectives: Synthesis Description of Adverse Effects in Patients with Non-Hodgkin's Lymphoma Undergoing Chemotherapy According to the R-CHOP Protocol. Subjects and Methods: Overview of literature: articles, studies, lectures, textbooks from three databases: PubMed, Google Scholar, and ScienceDirect, meeting research criteria. Results: 300 documents were found. After analysis, 12 articles were included in the study: retrospective design studies 91.6% (11), clinical studies 8.3% (1), and the sample size of the studies ranged from at least 7 to a maximum of 181 people. The average age ranged from 23-83 years, with the most common age group being 30-60. Male/female ratio: 1.94/1. The 12 articles showed common adverse effects in patients treated with the R-CHOP chemotherapy regimen. Conclusion: The most common clinical symptoms in patients treated for non-Hodgkin's lymphoma in the head and neck area are hair loss, nausea, and symptoms due to leukopenia; leukocyte stimulation yielded positive results

Article Details

Keywords

Adverse effects of R-CHOP, head and neck non-hodgkin’s lymphoma

References

1. Mafra A, Laversanne M, Gospodarowicz M, et al. Global patterns of non-Hodgkin lymphoma in 2020. Int J Cancer. 2022;151(9):1474-1481. doi:10.1002/ijc.34163
2. Yamanaka N, Harabuchi Y, Sambe S, et al. Non-Hodgkin’s lymphoma of Waldeyer’s ring and nasal cavity. Clinical and immunologic aspects. Cancer. 1985;56(4):768-776. doi:10.1002/1097-0142 (19850815) 56:4<768::aid-cncr2820560412>3.0.co;2-w
3. Bartlett NL, Wilson WH, Jung SH, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799. doi:10.1200/ JCO.18.01994
4. Singh R, Shaik S, Negi BS, et al. Non-Hodgkin’s lymphoma: A review. J Family Med Prim Care. 2020;9(4):1834-1840. doi:10.4103/jfmpc.jfmpc_1037_19
5. Pierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018;8:163. doi: 10.3389/fonc. 2018.00163
6. Nguyễn TB, Tống XT. Nghiên cứu đặc điểm lâm sàng, mô bệnh học u Lympho ác tính không Hodgkin vùng đồ cổ = Assessment of clinical features and histopathologic type of non-Hodgkin lymphoma in head and neck. Published online 2020. Accessed November 30, 2023. https://scholar.dlu.edu.vn/thuvienso/handle/DLU123456789/140885
7. F L. Tập Tranh Giải Phẫu Tai Mũi Họng. Vụ khoa học và đào tạo,; 1991.
8. Johnson J, Rosen CA, Bailey BJ. Bailey’s Head and Neck Surgery: Otolaryngology. Lippincott Williams & Wilkins; 2013.
9. Kwak YK, Choi BO, Kim SH, Lee JH, Kang DG, Lee JH. Treatment outcome of diffuse large B-cell lymphoma involving the head and neck. Medicine (Baltimore). 2017;96(25):e7268. doi: 10.1097/MD.0000000000007268
10. Lisenko K, Dingeldein G, Cremer M, et al. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. BMC Cancer. 2017;17(1):359. doi:10.1186/s12885-017-3332-3